{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T16:55:03Z","timestamp":1791305703492,"version":"4.3.1"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Res"],"DOI":"10.1038\/s41390-026-05588-y","type":"journal-article","created":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T16:23:15Z","timestamp":1791303795000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Editing the rulebook: building the policy environment for children to access gene therapy"],"prefix":"10.1038","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7443-7446","authenticated-orcid":false,"given":"Christian D.","family":"Pulcini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kao-Ping","family":"Chua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rena M.","family":"Conti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"On behalf of the Pediatric Policy Council","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Keller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly","family":"Montez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maya","family":"Ragavan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Lorch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie","family":"Plax","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph St.","family":"Geme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashwini","family":"Lakshmanan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J.","family":"Mariani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,6]]},"reference":[{"key":"5588_CR1","doi-asserted-by":"publisher","unstructured":"Pan Y., et al. The future of pediatric gene therapy: CRISPR-Cas9, AI, and personalized medicine. Pediatr Res. https:\/\/doi.org\/10.1038\/s41390-026-05270-3 (2026).","DOI":"10.1038\/s41390-026-05270-3"},{"key":"5588_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2024.122685","volume":"348","author":"T Mohammadian Gol","year":"2024","unstructured":"Mohammadian Gol, T. et al. Gene therapy in pediatrics \u2013 clinical studies and approved drugs (as of 2023). Life Sci. 348, 122685 https:\/\/doi.org\/10.1016\/j.lfs.2024.122685 (2024).","journal-title":"Life Sci."},{"key":"5588_CR3","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.pediatrneurol.2021.09.011","volume":"125","author":"RA Shellhaas","year":"2021","unstructured":"Shellhaas, R. A. et al. Gene-targeted therapies in pediatric neurology: challenges and opportunities in diagnosis and delivery. Pediatr. Neurol. 125, 53\u201357 https:\/\/doi.org\/10.1016\/j.pediatrneurol.2021.09.011 (2021).","journal-title":"Pediatr. Neurol."},{"key":"5588_CR4","unstructured":"FDA approves Lenmeldy: $4.25 million gene therapy for rare childhood disease MLD. MedPath. Accessed 23 August 2026 https:\/\/trial.medpath.com\/news\/fda-approves-lenmeldy-4-25-million-gene-therapy-for-rare-childhood-disease-mld (2025)."},{"issue":"1","key":"5588_CR5","doi-asserted-by":"publisher","DOI":"10.1080\/20016689.2021.2022353","volume":"10","author":"M Nuijten","year":"2022","unstructured":"Nuijten, M. Pricing Zolgensma \u2013 the world\u2019s most expensive drug. J. Mark. Access Health Policy 10(1), 2022353 https:\/\/doi.org\/10.1080\/20016689.2021.2022353 (2022).","journal-title":"J. Mark. Access Health Policy"},{"issue":"9","key":"5588_CR6","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1001\/jama.2024.11703","volume":"332","author":"ERS Cliff","year":"2024","unstructured":"Cliff, E. R. S. & Tessema, F. A. The double-edged sword of extremely high prices for gene therapies in sickle cell disease. JAMA 332(9), 703\u2013704 https:\/\/doi.org\/10.1001\/jama.2024.11703 (2024).","journal-title":"JAMA"},{"key":"5588_CR7","unstructured":"Agboola F., et al. Launch price and access report. institute for clinical and economic review; Accessed 9 September 2026 https:\/\/icer.org\/assessment\/launch-price-and-access-2025\/#overview (2025)."},{"issue":"10","key":"5588_CR8","doi-asserted-by":"publisher","first-page":"1806","DOI":"10.1377\/hlthaff.2020.00595","volume":"39","author":"KP Chua","year":"2020","unstructured":"Chua, K. P. & Conti, R. M. Trends in orphan drug spending and out-of-pocket spending among US children, 2013\u201318. Health Aff. 39(10), 1806\u20131811 https:\/\/doi.org\/10.1377\/hlthaff.2020.00595 (2020).","journal-title":"Health Aff."},{"issue":"3","key":"5588_CR9","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1038\/s41587-023-02096-w","volume":"42","author":"M Vogel","year":"2024","unstructured":"Vogel, M., Kakani, P., Chandra, A. & Conti, R. M. Medicare price negotiation and pharmaceutical innovation following the Inflation Reduction Act. Nat. Biotechnol. 42(3), 406\u2013412 https:\/\/doi.org\/10.1038\/s41587-023-02096-w (2024).","journal-title":"Nat. Biotechnol."},{"issue":"22","key":"5588_CR10","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.1056\/NEJMoa2504747","volume":"392","author":"K Musunuru","year":"2025","unstructured":"Musunuru, K. et al. Patient-specific in vivo gene editing to treat a rare genetic disease. N. Engl. J. Med. 392(22), 2235\u20132243 https:\/\/doi.org\/10.1056\/NEJMoa2504747 (2025).","journal-title":"N. Engl. J. Med."},{"issue":"17","key":"5588_CR11","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1056\/NEJMoa1813279","volume":"381","author":"J Kim","year":"2019","unstructured":"Kim, J. et al. Patient-customized oligonucleotide therapy for a rare genetic disease. N. Engl. J. Med. 381(17), 1644\u20131652 https:\/\/doi.org\/10.1056\/NEJMoa1813279 (2019).","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"5588_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-026-04388-1","volume":"21","author":"N Nolen","year":"2026","unstructured":"Nolen, N. et al. Paying for precision: funding approaches for N-of-1 trials of individualized gene targeted therapies. Orphanet J. Rare Dis. 21(1), 281 https:\/\/doi.org\/10.1186\/s13023-026-04388-1 (2026).","journal-title":"Orphanet J. Rare Dis."},{"issue":"11","key":"5588_CR13","doi-asserted-by":"publisher","first-page":"5316","DOI":"10.1016\/j.ymthe.2025.09.049","volume":"33","author":"D Barrett","year":"2025","unstructured":"Barrett, D. et al. Overcoming barriers to commercially pre-viable gene and cell therapies for rare and ultra-rare diseases. Mol. Ther. 33(11), 5316\u20135326 https:\/\/doi.org\/10.1016\/j.ymthe.2025.09.049 (2025).","journal-title":"Mol. Ther."},{"key":"5588_CR14","unstructured":"Centers for Medicare & Medicaid Services. CMS expands access to lifesaving gene therapies through innovative state agreements. Accessed August 21, 2026. https:\/\/www.cms.gov\/newsroom\/press-releases\/cms-expands-access-lifesaving-gene-therapies-through-innovative-state-agreements (2025)."},{"key":"5588_CR15","unstructured":"Alliance of Community Health Plans. A lifeline for rare diseases. Accessed 9 September 2026. https:\/\/achp.org\/lifeline-for-rare-diseases\/ (2025)."},{"key":"5588_CR16","unstructured":"Katchmar A., Cohen A. B. A National Benefit For Cell And Gene Therapies: A Proposed Framework. Health Affairs Forefront.Accessed 9 September 2026. https:\/\/www.healthaffairs.org\/do\/10.1377\/forefront.20231226.981248\/full\/ (2024)."},{"key":"5588_CR17","unstructured":"U.S. Food and Drug Administration. FDA launches framework for accelerating development of individualized therapies for ultra-rare diseases. Accessed 23 August 2026. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-launches-framework-accelerating-development-individualized-therapies-ultra-rare-diseases (2026)."}],"container-title":["Pediatric Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41390-026-05588-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41390-026-05588-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41390-026-05588-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T16:23:18Z","timestamp":1791303798000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41390-026-05588-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,6]]},"references-count":17,"alternative-id":["5588"],"URL":"https:\/\/doi.org\/10.1038\/s41390-026-05588-y","relation":{},"ISSN":["0031-3998","1530-0447"],"issn-type":[{"value":"0031-3998","type":"print"},{"value":"1530-0447","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,6]]},"assertion":[{"value":"10 September 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This commentary does not report new human or animal research and did not require patient consent or institutional review.","order":1,"name":"Ethics","label":"Consent statement","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}